Introduction: Advances in protein analysis for the clinical laboratory

Clinical Chemistry

Volumn 56, Issue 2, 2010, Pages 149-151

  Hortin, Glen L ^a   Carr, Steven A ^b   Anderson, N Leigh ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c The Plasma Proteome Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ANTIGEN; ERYTHROCYTE ANTIGEN; INSULIN; PEPTIDE; PROTEIN; THYROGLOBULIN; TISSUE ANTIGEN; TROPONIN;

ANTIBODY AFFINITY; CANCER DIAGNOSIS; CEREBROSPINAL FLUID; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MASS SPECTROMETRY; OVARY CANCER; PROSTATE CANCER; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKERS; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC TESTS, ROUTINE; HUMANS; PROTEINS;

EID: 75749139373     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.132803     Document Type: Editorial

References (16)

1. Sanger F. The chemistry of insulin: Nobel lecture, December 11, 1958. http://nobelprize.org/nobel-prizes/chemistry/laureates/1958/sanger-lecture.pdf (Accessed November 2009).
2. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67.
3. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010;56:177-85.
4. Carr SA, Anderson L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory. Clin Chem 2008;54: 1749-52.
5. Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51:3-5.
6. Hortin GL, Jortani SA, Ritchie JC, Valdes R, Chan DW. Proteomics: a new diagnostic frontier. Clin Chem 2006;52:1218-22.
7. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotech 2006;24:971-83.
8. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006;6:961-7.
9. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006;52:1223-37.
10. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008;54:53-60.
11. Timms JF, Cramer R, Camuzeaux S, Tiss A, Smith C, Burford B, et al. Peptides generated ex vivo from serum proteins by tumour-specific exopeptidases are not useful biomarkers in ovarian cancer. Clin Chem 2010;56:262-71
12. Hoofnagel AN, Becker JO, Wener MH, Heinecke JW. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008;54:1796-804.
13. Keshishian H, Burgess M, Shi X, Mani DR, Kuhn E, Addona T, et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics 2009;8: 2339-49.
14. Kuhn E, Addona T, Keshishian H, Burgess B, Mani DR, Sabatine MS, et al. Developing multiplexed assays for troponin I and interleukin 33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009;55:1108-17.
15. Borges CR, Rehder DS, Jarvis JW, Schaab MR, Oran PE, Nelson RW. Fulllength characterization of proteins in human populations. Clin Chem 2010; 56:202-11.
16. US Food and Drug Administration. FDA clears a test for ovarian cancer: test can help identify potential malignancies, guide surgical decisions. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm182057.htm (Accessed November 2009).